Psoriasis is far more than a cosmetic nuisance. It is a chronic immune-mediated condition affecting roughly two to three percent of the global population, characterized by scaly, red, often itchy plaques driven by runaway inflammatory signaling in the skin. Decades of research have established that the disease is not confined to the epidermis: people with psoriasis carry elevated risks of cardiovascular disease, metabolic syndrome, depression, and psoriatic arthritis. Yet diagnosing and tracking the systemic inflammatory burden of psoriasis remains challenging in everyday clinical practice. Physicians typically rely on visual assessment of skin involvement and, when available, inflammatory markers such as C-reactive protein, none of which perfectly capture the whole-body picture. This gap has fueled an intense search for inexpensive, reproducible biomarkers that reflect the interplay between inflammation and nutrition.

Enter RAR, a composite index that combines two routinely measured blood values into a single number. The first component, red cell distribution width, or RDW, quantifies the variation in size among circulating red blood cells. A narrow, uniform population of erythrocytes yields a low RDW, while a heterogeneous mix pushes the value upward. Hematologists have long known that RDW rises in conditions of chronic inflammation, oxidative stress, nutritional deficiency, and disordered erythropoiesis, and elevated RDW has repeatedly been linked to worse outcomes in heart failure, myocardial infarction, sepsis, stroke, and chronic kidney disease. The second component, serum albumin, is the most abundant protein in human plasma, synthesized by the liver and well established as a negative acute-phase reactant: when systemic inflammation flares, albumin synthesis is suppressed and levels fall. Albumin also serves as a broad proxy for nutritional status, liver function, and even the anticoagulant properties of blood plasma.

By dividing RDW by albumin concentration, RAR effectively captures two sides of the inflammatory coin at once: a numerator that climbs as inflammation and oxidative stress perturb red cell maturation, and a denominator that sinks as the same inflammatory cascade dampens hepatic protein synthesis. The ratio has already shown prognostic value in heart failure, atrial fibrillation, rheumatoid arthritis, diabetes-related foot ulcers, and acute ischemic stroke, where higher values tracked with increased mortality. What remained unclear was whether RAR also relates to the prevalence of a chronic inflammatory skin disease in the general population, which is precisely the question the research team, led by dermatologists at The First Affiliated Hospital of Jinan University in Guangzhou, China, set out to answer.

To do so, the investigators turned to the National Health and Nutrition Examination Survey, or NHANES, a long-running program of the National Centers for Health Statistics that combines interviews, physical examinations, and laboratory testing on a sample designed to represent the civilian, non-institutionalized US population. The team pooled six survey cycles spanning 2003 to 2006 and 2009 to 2014, yielding 11,668 adults with complete data on both RDW and serum albumin. Within this cohort, 280 participants reported a clinician-confirmed diagnosis of psoriasis. The researchers calculated RAR for every participant, applied a natural logarithmic transformation to normalize its distribution, and then deployed multivariable logistic regression to ask whether ln-RAR was independently associated with psoriasis prevalence after accounting for a comprehensive set of potential confounders.

The results were striking. In the fully adjusted model, higher ln-RAR was independently associated with roughly 3.57-fold higher odds of psoriasis, with a 95 percent confidence interval of 1.37 to 8.92 and a P value of 0.003. In other words, even after statistical adjustment for demographic, lifestyle, and clinical factors, adults whose blood chemistry reflected greater red cell size variability relative to their albumin levels were markedly more likely to carry a psoriasis diagnosis. Crucially, the association was not confined to a narrow slice of the data. Restricted cubic spline analysis, a flexible modeling technique that allows the relationship between exposure and outcome to take any shape, confirmed a linear dose-response pattern: the risk of psoriasis rose steadily and proportionally across the RAR spectrum, with no evidence of a threshold effect or non-linear inflection.

Robustness checks reinforced the central finding. In subgroup analyses stratified across clinically relevant population segments, the effect size of RAR on psoriasis presence remained stable, with all interaction P values exceeding 0.05, meaning the association did not meaningfully differ by subgroup membership. Sensitivity analyses, which re-ran the models under alternative assumptions and specifications, produced results consistent with the primary analysis. For a cross-sectional study, which by design captures a single moment in time and cannot establish causation, this degree of internal consistency across analytic approaches lends considerable weight to the conclusion that the RAR-psoriasis link is not a statistical artifact.

The biological plausibility of the association is grounded in well-characterized mechanisms. Chronic inflammation in psoriasis is driven by cytokines such as tumor necrosis factor-alpha, interleukin-17, and interleukin-23, which orchestrate the keratinocyte hyperproliferation and immune cell infiltration visible in plaques while simultaneously exerting systemic effects. These mediators promote oxidative stress that damages red blood cell membranes and shortens erythrocyte survival, widening the RDW. They also suppress albumin synthesis and increase vascular permeability, lowering serum albumin. Recent experimental work has even suggested that abnormal erythrocytes, filtered inefficiently by the spleen, may create a hypoxic microenvironment that favors psoriatic inflammation, providing a direct mechanistic bridge between red cell abnormalities and skin disease. RAR, by integrating both an elevated RDW and a depressed albumin into one metric, may therefore function as a compact readout of the very inflammatory and hypoxic milieu that sustains psoriasis.

The study is not without limitations, and the authors are careful to frame their findings as hypothesis-generating rather than practice-changing. The cross-sectional design means the data show association, not causation: it is equally possible that subclinical inflammation from early psoriasis alters blood indices, or that shared upstream factors drive both. Psoriasis status relied on self-reported clinician diagnosis, which may undercount mild or undiagnosed cases, and the analysis could not capture disease severity, duration, or treatment status. The researchers explicitly call for prospective studies to confirm the findings and to determine whether RAR can predict incident psoriasis, track disease activity over time, or respond to effective therapy. Prior work has shown that biologic treatment can reduce measurable vascular inflammation in psoriasis patients, raising the tantalizing question of whether successful treatment also normalizes RAR.

Still, the appeal of the finding lies in its accessibility. RDW and albumin are measured in virtually every hospital laboratory on the planet, typically for a few dollars, with no specialized equipment or additional blood draw. If prospective research validates RAR as a psoriasis marker, it could offer clinicians a zero-cost screening signal embedded in tests already ordered for other reasons, potentially prompting earlier dermatology referral for patients whose skin symptoms have gone unreported. It could also aid research into the systemic burden of psoriasis, complementing established markers like C-reactive protein and newer indices such as the neutrophil percentage-to-albumin ratio. For now, the message is one of cautious excitement: a humble ratio, computed from two of the oldest measurements in medicine, appears to carry a whisper of information about one of dermatology’s most visible inflammatory diseases, and the scientific community will be watching closely as larger, longitudinal studies put that whisper to the test.

Subject of Research: Association between the red blood cell distribution width-to-albumin ratio and psoriasis prevalence in US adults

Article Title: The association between adult red blood cell width to albumin ratio (RAR) and psoriasis: a retrospective cross-sectional study

Article References: Gao, A., Wei, Z., Ye, X., Shao, W., & Hu, Y. (2026). The association between adult red blood cell width to albumin ratio (RAR) and psoriasis: a retrospective cross-sectional study. Archives of Dermatological Research, 318(1), Article 447. https://doi.org/10.1007/s00403-026-04922-y

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04922-y

Keywords: psoriasis, RAR, red cell distribution width, albumin, biomarker, NHANES, inflammation, cross-sectional study, dermatology, logistic regression, systemic inflammation, epidemiology

The research, led by Xia Sun and Tianrong Pan of the Second Affiliated Hospital of Anhui Medical University along with colleagues at Lishui Hospital of Traditional Chinese Medicine, took a retrospective look at 150 patients with type 2 diabetes who were treated at a tertiary hospital between January 2022 and December 2023. All patients met the 1999 World Health Organization diagnostic criteria for diabetes. Of the 150 individuals in the cohort, 92 had already developed diabetic retinopathy, giving the researchers a substantial group of both affected and unaffected patients to compare. The goal was not simply to catalog differences between the two groups but to build a working mathematical model that could estimate an individual patient’s risk.

The scientific rationale behind the study rests on a growing body of evidence that diabetic retinopathy is not merely a disease of high blood sugar damaging tiny retinal vessels. Subclinical inflammation and endothelial dysfunction—the gradual breakdown of the delicate inner lining of blood vessels—appear to play central roles in the earliest stages of retinal injury. Two families of biological markers have attracted attention in this context. The first is adipokines, signaling molecules secreted by adipose tissue that influence metabolism, inflammation, and vascular health. The second is hematological indices, particularly red cell distribution width, or RDW, a measure of the variation in the size of circulating red blood cells that has increasingly been recognized as a marker of systemic inflammation and oxidative stress.

Among the adipokines examined were omentin-1, adiponectin, apelin, and nesfatin-1, each with distinct and sometimes counterintuitive relationships to retinal disease. Using multivariate logistic regression, the researchers found that higher levels of omentin-1 and apelin were associated with an increased risk of diabetic retinopathy, while higher nesfatin-1 levels were associated with a reduced risk. Adiponectin, one of the most extensively studied fat-derived hormones, was incorporated into the final prediction model as well. The findings underscore how complex the biology of adipose tissue is in diabetes: molecules that are often described as protective in metabolic disease can behave differently when viewed through the lens of microvascular complications.

The hematological and biochemical picture that emerged was equally instructive. Patients with a mean arterial pressure above 120 mmHg faced elevated risk, as did those with abnormal levels of the liver enzymes aspartate aminotransferase and gamma-glutamyl transpeptidase, and those with high blood urea nitrogen, a marker of kidney function. Conversely, several factors appeared protective in the statistical analysis: higher high-density lipoprotein cholesterol, abnormal alanine aminotransferase, and high insulin resistance as measured by the homeostasis model assessment were each associated with reduced risk of retinopathy. Some of these associations—particularly the counterintuitive direction of the insulin resistance finding—highlight the hazards of interpreting retrospective data and the need for caution before drawing biological conclusions.

To translate these associations into a practical tool, the team constructed a prediction model and evaluated its performance using receiver operating characteristic analysis, the standard method for assessing how well a diagnostic or prognostic model separates those who develop a condition from those who do not. The apparent area under the curve, or AUC, was 0.921 with a 95 percent confidence interval of 0.880 to 0.962, a figure that in clinical terms suggests excellent discrimination. Because apparent performance almost always overstates how a model will behave in new patients, the researchers applied bootstrap internal validation, a resampling technique that estimates the degree of overfitting. The optimism-corrected AUC came out at 0.873 with a confidence interval of 0.821 to 0.925, still comfortably in the range considered good for a clinical prediction model.

Discrimination, however, is only half the story. A prediction model must also be well calibrated, meaning that when it says a patient has a 40 percent risk, roughly 40 percent of similar patients should actually develop the disease. The Hosmer-Lemeshow test suggested adequate calibration with a p value of 0.293, but the more visually informative calibration plot told a subtler tale. The model systematically underestimated risk in the intermediate probability range between 0.2 and 0.6 and overestimated risk around the 0.7 mark. The authors were candid about this discrepancy, describing the calibration as suboptimal and flagging it as an issue that would need to be addressed before any clinical deployment. This kind of transparency is increasingly valued in the prediction-model literature, where inflated claims of readiness have historically undermined trust in such tools.

The researchers also performed decision-curve analysis, a technique that quantifies the net benefit of using a model to guide clinical decisions across a range of risk thresholds. The model demonstrated positive net benefit across threshold probabilities of 10 percent to 60 percent, suggesting that within that band, acting on the model’s predictions would yield more benefit than the default strategies of treating all patients or treating none. In practical terms, this means an ophthalmology or endocrinology service could, in principle, use the model to prioritize patients for retinal screening, reserving scarce imaging and specialist resources for those whose calculated risk justifies closer surveillance.

Despite the encouraging numbers, the authors are careful to frame the study as a starting point rather than a finished clinical instrument. The cohort was modest in size, drawn from a single tertiary hospital, and analyzed retrospectively, all of which limit generalizability. The model has not yet been tested in an independent external cohort, the gold standard for demonstrating that a prediction tool performs as advertised outside the data that shaped it. The authors explicitly state that external validation and model recalibration are needed before clinical application. The calibration deviations observed in the intermediate risk range, where most clinical decisions are actually made, reinforce that recommendation.

Even with those caveats, the study adds to a compelling trend in diabetes research: the search for affordable, widely available biomarkers that can stratify risk before irreversible damage occurs. Adipokines and RDW can be measured from standard blood samples in most hospital laboratories, and combining them with blood pressure, liver enzymes, and kidney markers requires no new technology. If future prospective studies confirm the model’s performance and correct its calibration, the approach could help shift diabetic retinopathy care from reactive screening toward proactive risk management, catching the disease in time to preserve vision for the millions of people living with type 2 diabetes worldwide.

Subject of Research: A clinical prediction model for diabetic retinopathy in type 2 diabetes using adipokines and red cell distribution width

Article Title: A prediction model for diabetic retinopathy incorporating adipokines and red cell distribution width among patients with type 2 diabetes

Article References: Sun, X., Qiu, W., Chen, X., Zheng, P., Dan, L., Wu, J., & Pan, T. (2026). A prediction model for diabetic retinopathy incorporating adipokines and red cell distribution width among patients with type 2 diabetes. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02546-x

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02546-x

Keywords: diabetic retinopathy, type 2 diabetes, adipokines, omentin-1, adiponectin, red cell distribution width, prediction model, apelin, nesfatin-1, logistic regression, ROC analysis, endothelial dysfunction

The research, published in BMC Endocrine Disorders, drew on the MIMIC-IV database, a vast, de-identified repository of intensive care unit records maintained through PhysioNet and approved by the institutional review boards of the Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center. After applying strict inclusion and exclusion criteria, the investigators identified 8,201 patients who had been diagnosed with type 2 diabetes mellitus during an ICU stay. Because the data were fully anonymized and the design was retrospective, individual informed consent was not required, and the study was conducted in accordance with the Declaration of Helsinki.

To understand why this ratio matters, it helps to unpack its two components. Hemoglobin is the iron-containing protein inside red blood cells that carries oxygen from the lungs to every tissue in the body, including the delicate capillary networks of the kidney. Red cell distribution width, or RDW, is a measure of how much the sizes of circulating red blood cells vary from one another. A high RDW signals anisocytosis, a heterogeneity in cell size that has been associated in numerous studies with inflammation, oxidative stress, nutritional deficiencies, and disturbed red blood cell production in the bone marrow. Both hemoglobin levels and RDW have previously been shown to correlate with diabetic kidney disease, which is precisely why the authors reasoned that combining them into a single ratio might capture more information than either marker alone.

The logic behind the combination is straightforward. Hemoglobin tends to fall as diabetic kidney disease progresses, in part because damaged kidneys produce less erythropoietin, the hormone that stimulates red blood cell production, and in part because of the chronic inflammatory state that accompanies renal decline. RDW, meanwhile, tends to rise as the marrow responds unevenly to these stresses, releasing red cells of increasingly disparate sizes. Dividing hemoglobin by RDW therefore creates an index that moves downward when both abnormalities are present, potentially offering a single integrated signal of the physiological turbulence that diabetic kidney disease generates.

To test that idea rigorously, the team used stratified random sampling by diabetic kidney disease status to split their cohort into a training set of 5,741 cases and a validation set of 2,460 cases, in a seven-to-three ratio. This division matters because it allows a finding discovered in one portion of the data to be checked against an independent portion, guarding against the statistical flattery that can arise when researchers analyze and validate on the same patients. The stratification by disease status ensured that both sets contained comparable proportions of patients with and without diabetic kidney disease, preserving the balance needed for fair comparison.

The analytical toolkit combined three complementary techniques. Multivariate logistic regression, which estimates the association between an exposure and an outcome while adjusting for other variables, showed that elevated HRR was negatively correlated with the risk of diabetic kidney disease, a relationship that reached statistical significance. In other words, patients with higher ratios were less likely to have the disease, and those with lower ratios were more likely to have it, exactly the direction the underlying biology would predict.

Next, the researchers turned to receiver operating characteristic curve analysis, a standard method for quantifying how well a continuous marker discriminates between two groups. The area under the ROC curve reflects this discriminatory power, with a value of 0.5 indicating performance no better than a coin flip and a value of 1.0 indicating perfect separation. When the team compared HRR against hemoglobin alone and RDW alone, the ratio demonstrated slightly better discriminatory performance for diabetic kidney disease than either single indicator, in both the training and the validation sets, with the differences reaching statistical significance. This is a meaningful, if modest, advantage: it suggests that the integrated ratio genuinely carries information that neither component captures on its own, rather than simply repackaging the same signal.

Perhaps the most intriguing result came from restricted cubic splines, a flexible regression technique that allows researchers to map out nonlinear dose-response relationships without imposing a predetermined straight line. The spline analysis confirmed that the relationship between HRR and diabetic kidney disease risk was not linear but curved, with a turning point identified at an HRR value of 6.9492. Below that threshold, the association between the ratio and disease risk behaved differently than above it, hinting that the marker may be most informative within a specific physiological range. Nonlinear findings of this kind are increasingly recognized as important in biomarker research, because they can reveal thresholds at which risk accelerates or plateaus, information that a simple linear model would smooth over and obscure.

The clinical appeal of HRR lies in its accessibility. Unlike specialized renal markers or imaging studies, the ratio requires no additional blood draw, no extra cost, and no laboratory beyond the standard complete blood count that virtually every hospitalized patient already receives. For patients with type 2 diabetes admitted to intensive care, a low HRR could serve as an inexpensive red flag prompting clinicians to look more closely at kidney function, tighten glycemic management, or consider nephroprotective strategies earlier in the hospitalization. The authors caution, however, that the discriminatory advantage of HRR over its individual components was slight, and that a cross-sectional design captures a single moment in time rather than tracking disease development, so the ratio cannot establish that low HRR precedes or causes kidney damage.

Those caveats frame the study as a promising observational association rather than a ready-made diagnostic test. The team, led by Feng Li, Yali Li, Hongsheng Ren, Lujing Meng, and corresponding author Jiefang Zhang, based at Heze Municipal Hospital, the Provincial Hospital of the First Medical University of Shandong Province, and Qingdao Municipal Hospital, acknowledges that prospective studies will be needed to determine whether HRR can predict the future onset or progression of diabetic kidney disease, and whether it adds value beyond established measures such as estimated glomerular filtration rate and urinary albumin. Still, the findings add to a growing body of evidence that routine hematological indices, examined with modern statistical tools, can illuminate the inflammatory and hematological fingerprints of diabetic complications. In a disease that affects more than half a billion people worldwide and quietly destroys kidneys along the way, even a slightly sharper, essentially free early warning signal could prove valuable. The work was supported by the Key Medical and Health Discipline of Shandong Province, and the full open-access article is available under a Creative Commons license for clinicians and researchers who wish to examine the methods in detail.

Subject of Research: Association between the hemoglobin-to-red cell distribution width ratio and diabetic kidney disease in patients with type 2 diabetes

Article Title: Association between hemoglobin-to-red cell distribution width ratio (HRR) and diabetic kidney disease: a cross-sectional study based on the MIMIC-IV database

Article References: Li, F., Li, Y., Ren, H., Meng, L., & Zhang, J. (2026). Association between hemoglobin-to-red cell distribution width ratio (HRR) and diabetic kidney disease: a cross-sectional study based on the MIMIC-IV database. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02588-1

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02588-1

Keywords: diabetic kidney disease, type 2 diabetes, hemoglobin, red cell distribution width, HRR, MIMIC-IV, biomarker, ICU, cross-sectional study, logistic regression, restricted cubic splines, nephrology

The research, led by Mirko Di Rosa and Luca Soraci of IRCCS INRCA in Cosenza, Italy, together with colleagues at the University of Calabria and partner institutions, pooled individual-level data from four prospective European cohorts of older adults. The cohorts were deliberately heterogeneous: 812 community-dwelling older people from the ECHA-PC-MUSA studies, 813 nursing home residents from the SADEL cohort, 579 long-lived individuals and area-matched controls from the Genetics of Healthy Ageing project, and 4,400 hospitalized patients from the REPORTAGE project. In total, 6,604 people were followed for up to five years, and the mean age of the pooled sample was 84.8 years, with a standard deviation of 9.2 years. That breadth of settings is precisely what makes the analysis unusual; most previous studies of RDW and mortality have examined a single clinical population, leaving open the question of whether the marker truly travels across the diverse worlds of home, hospital, and long-term care.

Technically, RDW is reported as a coefficient of variation, the standard deviation of red cell volume divided by the mean corpuscular volume, multiplied by one hundred. It is generated automatically by automated haematology analysers at no additional cost, which is part of its appeal as a potential screening tool. In this study the primary exposure was an RDW-CV of 15 percent or higher, a threshold commonly used to flag anisocytosis, the technical term for increased variability in red cell size. Among the European participants, 41.4 percent met this criterion, and over the five-year follow-up period 69.9 percent of the cohort died, a striking figure that reflects the advanced age and clinical vulnerability of the populations studied.

To test whether elevated RDW was an independent predictor of death rather than a bystander marker of known risk factors, the investigators used multilevel Cox proportional hazards regression, treating the cohort of origin as a random effect. The models adjusted for a formidable battery of geriatric prognostic factors: age, sex, the presence of anaemia, serum albumin, the neutrophil-to-lymphocyte ratio as an index of systemic inflammation, the number of chronic diseases and medications, and impairment in activities of daily living. The models also pre-specified stratification at age 85, allowing the association to be examined separately in the oldest-old, a group in which mortality prediction is notoriously difficult because standard risk factors often lose discriminatory power.

The headline result was unambiguous. Older adults with RDW-CV at or above 15 percent had a 58 percent higher hazard of death during follow-up than those below the threshold, with a pooled adjusted hazard ratio of 1.58 and a 95 percent confidence interval running from 1.48 to 1.68, a finding highly statistically significant at p less than 0.001. Just as important as the magnitude was the consistency: between-cohort heterogeneity, quantified by the theta statistic, was minimal at 0.06, and the direction of the association was concordant in three of the four cohorts. In epidemiological terms, this suggests that the relationship is not an artefact of any single population or care setting but a robust phenomenon that persists whether the blood was drawn in a nursing home, a hospital ward, or a community clinic.

Replication is where many biomarker studies falter, so the team took the additional step of validating their findings externally in an entirely different healthcare system. They analysed 2,471 participants from the 2016 wave of the Health and Retirement Study, a large, nationally representative survey of older Americans. Once again, the elevated-RDW group showed significantly higher mortality, with a hazard ratio whose 95 percent confidence interval extended from 1.23 to 2.19 and a p value below 0.001. The fact that the association survived in a transatlantic sample, with different ancestry profiles, laboratory platforms, and care structures, strengthens the case that RDW captures something fundamental about biological risk rather than a local idiosyncrasy of Italian geriatric medicine.

Why should the variability of red blood cell size carry information about survival? The most widely discussed mechanism implicates chronic, low-grade systemic inflammation and its effects on erythropoiesis, the production of red cells in the bone marrow. Inflammatory cytokines disturb iron metabolism, shorten red cell lifespan, and disrupt the careful regulation of cell volume during maturation, producing a wider distribution of cell sizes. Elevated RDW has also been linked to oxidative stress, nutritional deficiencies, renal dysfunction, and subtle derangements of haematopoietic stem cell dynamics. In this sense, the authors argue, RDW may act as an integrative readout of physiological dysregulation, a single number that summarises the accumulated wear on multiple organ systems. Its independence from the neutrophil-to-lymphocyte ratio and albumin in the adjusted models suggests it is not simply proxying inflammation or malnutrition but adds a distinct dimension of prognostic information.

The association was strongest in the oldest-old, participants aged 85 and above, which is where the clinical implications become most interesting. Predicting mortality in very old patients is a persistent challenge for geriatric medicine; chronological age alone is a blunt instrument, and comprehensive geriatric assessment, while valuable, is time-consuming and requires trained personnel. A marker that costs nothing extra, is already reported on every blood count, and performs at a fixed cut-off across community, nursing home, and hospital populations could help clinicians stratify risk quickly at the bedside. It might, for example, inform decisions about the intensity of investigations, the appropriateness of aggressive interventions, or the prioritisation of patients for closer monitoring. The researchers are careful, however, to frame RDW as a prognostic indicator, not a deterministic verdict; a hazard ratio of 1.58 describes average risk at the population level, and individual outcomes will vary widely.

Several caveats temper the enthusiasm. This is an observational analysis, so elevated RDW identifies association rather than proven causation, and there is as yet no evidence that lowering RDW would change survival. The exposure was measured at a single time point, leaving open questions about the value of tracking RDW trajectories over time, and although the adjustment set was unusually comprehensive for a biomarker study, residual confounding can never be fully excluded. The predominance of Italian cohorts in the pooled European sample also invites replication in other national contexts, even given the American validation. Nonetheless, the study clears a high bar: a fixed, pre-specified threshold, individual-level pooling across markedly different care settings, adjustment for the major geriatric prognostic factors including anaemia, functional status, inflammation, and nutrition, minimal heterogeneity, and external replication in a second continent. Few routinely available laboratory measures can claim a comparable evidentiary pedigree.

The broader lesson may be about where medicine should look for its next generation of risk markers. As automated analysers quietly compute dozens of derived indices with every routine sample, some of the most informative signals may already be sitting in electronic health records, unexamined. Red cell distribution width, a number most patients have never heard of, now has credible evidence behind it as an independent predictor of five-year mortality in older adults across the full spectrum of care, from independent living to intensive hospital treatment. For a rapidly ageing global population, and for clinicians searching for cheap, scalable tools to guide geriatric care, a modest column of digits on a standard blood report may prove to be one of the most consequential numbers in the chart.

Subject of Research: Red cell distribution width as an independent predictor of five-year all-cause mortality in older adults across diverse care settings

Article Title: Red cell distribution width and 5-year mortality across older adult care settings: a pooled European cohort analysis with US validation

Article References: Red cell distribution width and 5-year mortality across older adult care settings: a pooled European cohort analysis with US validation. (n.d.). https://doi.org/10.1186/s12967-026-08997-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08997-z

Keywords: red cell distribution width, RDW, mortality, aging, geriatrics, complete blood count, oldest old, prognosis, cohort study, anaemia, inflammation, biomarker